medline.ch Onkologie Urologische Tumoren

	Real-World Outcomes and Prognostic Factors of Immune Checkpoint Inhibitor Rechallenge for Metastatic Renal Cell Carcinoma: A Multicenter Study. Int J Urol Matsumoto S, Tanaka H, Matsushita Y, Kojima T, Kurahashi T, Bando Y, Kimura T, Nishiyama N, Yamashita S, Taniguchi H, Goto S, Fukuda H, Kawasaki Y, Kitamura H, Miyake H, Fujii Y, Japanese Urological Oncology Group. PMID: 42385189 [PubMed - indexed for MEDLINE]
	Outcomes of Gemcitabine, Oxaliplatin, and Paclitaxel Salvage Chemotherapy in Japanese Patients With Relapsed or Refractory Germ Cell Tumors. Int J Urol Aigase T, Kouno T, Kubo H, Matsumoto T, Suzuki A, Nakaigawa N, Kishida T. PMID: 42385183 [PubMed - indexed for MEDLINE]
	Prognostic Factors for Relapse and Mortality Risk in Chilean Patients With Testicular Cancer: A Retrospective Cohort Study. JCO Glob Oncol Ríos-Correa V, Bennett-Laso J, Guerra-Pérez D, Jiménez-Galindo M, Avendaño-Arriagada F, Correa-Duque M, Villarroel A, Miranda C, Ibañez C, Majerson A, Briones-Carvajal J. PMID: 42385096 [PubMed - indexed for MEDLINE]
	Evaluation and comparison of voided urine and bladder washing cytologies according to the Paris system. Rev Assoc Med Bras (1992) Bulut A, K. PMID: 42385039 [PubMed - indexed for MEDLINE]
	Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma. N Engl J Med Choueiri TK, Motzer RJ, Karam JA, Yip W, Suárez C, Ye D, He Z, Caglevic C, Ferguson T, Chang YH, Rojas C, Iacovelli R, Ürün Y, Verzoni E, Vázquez Limón JC, Porta C, Uzzo RG, Lee JL, Venugopal B, McKay RR, Hammers H, Miyake H, Chahoud J, Liu H, Burgents JE, Sharma M, Powles TB, LITESPARK-022 Investigators. PMID: 42384869 [PubMed - indexed for MEDLINE]
	First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial Carcinoma. JAMA Netw Open Velasquez EL, Titus RS, Nguyen DD, Riveros C, Lalani AK, Kaushik D, Sonpavde GP, Grivas P, Wallis CJD, Satkunasivam R. PMID: 42384383 [PubMed - indexed for MEDLINE]
	The Prognostic Value of (68)Ga-PSMA and (18)F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with (177)Lu-EB-PSMA. Ann Nucl Med Chen X, Peng Y, Zheng Q, Lai Y, Cheng H, Zhu Z, Wang G, Zang J. PMID: 42384311 [PubMed - as supplied by publisher]
	A diagnostic pitfall in suspected giant cell arteritis: metastatic renal cell carcinoma mimicking the temporal artery halo sign on ultrasound. Rheumatol Int Yamancan G, Karata. PMID: 42384226 [PubMed - in process]
	Diagnostic performance of PI-RADS and PSA density for detecting clinically significant prostate cancer. Arch Ital Urol Androl Shanaa W, Alnadhari I, Ali O, Abdeljaleel O, Abukhadijah HJ, Shamsodini A. PMID: 42383731 [PubMed - indexed for MEDLINE]
	The relationship of prostate cancer diagnosed by magnetic resonance imaging/transrectal ultrasound prostate fusion biopsy with standard and adjusted anogenital distances. Arch Ital Urol Androl Sinan Erdal F, Erbin A, Sekkeli S, Dizdaroglu C, Turkay R. PMID: 42383730 [PubMed - indexed for MEDLINE]
	Atypical urothelial cells investigation with automated urinalysis and expert review of microscopic sediment as early parameter for suspected bladder cancer patients. Arch Ital Urol Androl Noviardi DEPP, Seputra KP, Daryanto B, Dhani FK, Susianti H, Anita KW. PMID: 42383729 [PubMed - indexed for MEDLINE]
	Cost efficiency of ERAS protocols versus conventional method in urologic oncology: a systematic review of economic evaluations. Arch Ital Urol Androl Yanda A, Ismy J, Mauny MP, Khalilullah SA, Hidayatullah F. PMID: 42383727 [PubMed - indexed for MEDLINE]
	Adjuvant disitamab vedotin plus PD-1 blockade and gemcitabine/cisplatin in high-risk upper tract urothelial carcinoma: a two-stage real-world comparative study. Front Immunol Wang C, He S, Li D, Zhang B, Dai Y, Li C, Li X, Kang L, Yang S, Zhang S, Fan N, Chang H, Wu G, Yue Z, Ma J, Shang P. PMID: 42382757 [PubMed - indexed for MEDLINE]
	Urinary tract infection caused by rare yeast Vanrija humicola in a urothelial carcinoma patient: a case report and literature review. Front Immunol Qiu H, Du H, Li X, Wang X, Li Y, Bilal H, Xu B. PMID: 42382753 [PubMed - indexed for MEDLINE]
	Irreversible electroporation in focal therapy for prostate cancer: current status and future directions. Prostate Int Durazo-Ruiz FO, Roldán-Testillano R, Rodriguez-Sanchez L, Laguna MP, Mendez-Bisgaard LN, Arezki A, Elkhatib H, Hevia-Feliu A, Zhang K, Fainberg J, Perlis N, Rosette J, Miñana-López B, de Reijke TM, Anidjar M, Emberton M, Stricker PD, Sanchez-Salas R. PMID: 42382550 [PubMed]
	Therapeutic potentials of curcumin in prostate cancer: a comprehensive review of pathways and clinical prospects. Prostate Int Fattahi MR, Shoja F, Mojaradi MA, Nazarinezhad P, Dehghanbanadaki H, Arefnezhad R, Rezaei-Tazangi F, Azimi H. PMID: 42382546 [PubMed]
	Role of Postoperative Radiation Therapy After Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis. Adv Radiat Oncol Nohmi RL, Marques FC, Brito HC, Leite LM, Araujo DV. PMID: 42382432 [PubMed]
	Laparoscopic Versus Open Radical Nephrectomy for Renal Cell Carcinoma: A Retrospective Study. Indian J Surg Oncol Abouzid A, Shetiwy M, Hamdy M, Atallah K, Ezzat M, Elghaffar MA. PMID: 42381807 [PubMed]
	Correlation of Multiparametric MRI PIRADS Scoring with Histopathological Outcomes and Prognostic Significance in Prostate Cancer: A Tertiary Care Center Study. Indian J Surg Oncol R KJ, Charan NS, Ram CG, Mahendra S, Deepak B, S SA, Taruna Y, Meenakshi R. PMID: 42381792 [PubMed]
	Cardiovascular-Kidney-Metabolic Syndrome, Healthy Lifestyles, and Risk of Cancer Incidence and Mortality: AÂ Prospective Cohort Study. Int J Cancer Qie R, Liu H, Liu Y, Guo X, Chen Q, Xu H, Wang X, Kang R, Cheng C, Zhao M, Wang H, Zheng L, Liu S, Zhang S. PMID: 42381231 [PubMed - as supplied by publisher]

Artikel 1 - 20 / 179647

Seite 1 von 8983

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung